Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHANASDAQ:CNTBNASDAQ:MURANASDAQ:NBRV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$0.30-2.6%$0.29$0.22▼$3.67$11.52M3.031.58 million shs202,814 shsCNTBConnect Biopharma$1.00+3.0%$0.83$0.51▼$1.63$55.56M-0.2755,422 shs30,069 shsMURAMural Oncology$2.48$2.60$0.95▼$4.74$42.83M3.381.29 million shs39,523 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma0.00%-2.64%-2.22%+5.36%-88.87%CNTBConnect Biopharma0.00%-2.91%+27.91%+81.82%-34.21%MURAMural Oncology0.00%+1.22%-5.34%+96.83%-21.02%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHAAthira Pharma2.9046 of 5 stars3.03.00.00.03.21.71.3CNTBConnect Biopharma3.7946 of 5 stars3.55.00.00.03.82.50.6MURAMural Oncology3.4775 of 5 stars3.35.00.00.02.71.71.3NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHAAthira Pharma 2.00Hold$11.253,713.56% UpsideCNTBConnect Biopharma 3.00Buy$7.00600.00% UpsideMURAMural Oncology 2.50Moderate Buy$12.00383.87% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATHA, NBRV, MURA, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.003/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/ACNTBConnect Biopharma$26.03M2.13N/AN/A$1.67 per share0.60MURAMural OncologyN/AN/AN/AN/A$8.22 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHAAthira Pharma-$96.94M-$2.07N/AN/AN/AN/A-142.99%-106.40%7/30/2025 (Estimated)CNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)MURAMural Oncology-$128.51M-$7.67N/AN/AN/AN/A-83.39%-70.70%8/12/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ALatest ATHA, NBRV, MURA, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/A5/9/2025Q1 2025ATHAAthira Pharma-$0.20-$0.23-$0.03-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHAAthira PharmaN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHAAthira PharmaN/A7.267.26CNTBConnect Biopharma0.0110.2510.25MURAMural OncologyN/A5.085.08NBRVNabriva Therapeutics0.120.850.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHAAthira Pharma57.12%CNTBConnect Biopharma58.72%MURAMural Oncology80.21%NBRVNabriva Therapeutics0.27%Insider OwnershipCompanyInsider OwnershipATHAAthira Pharma19.80%CNTBConnect Biopharma22.60%MURAMural Oncology2.20%NBRVNabriva Therapeutics1.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHAAthira Pharma4039.04 million31.31 millionOptionableCNTBConnect Biopharma11055.56 million43.00 millionOptionableMURAMural Oncology11917.27 million16.89 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableATHA, NBRV, MURA, and CNTB HeadlinesRecent News About These CompaniesNabriva Therapeutics plc (NBRVF)October 19, 2024 | finance.yahoo.comMeitheal gains rights to ContempoJuly 20, 2024 | thepharmaletter.comTMeitheal gains rights to CONTEPO from Nabriva in North AmericaJuly 19, 2024 | pharmaceutical-technology.comPNabriva Therapeutics PLC NBRVFApril 13, 2024 | morningstar.comMNabriva Therapeutics files patent for a dosing regimen for fosfomycin treatmentDecember 22, 2023 | pharmaceutical-technology.comPArbutus Biopharma Corporation: Arbutus Appoints Two New ExecutivesJuly 11, 2023 | finanznachrichten.deNBRV - Nabriva Therapeutics plcMay 26, 2023 | finance.yahoo.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029February 28, 2023 | marketwatch.comNBRV Nabriva Therapeutics plcFebruary 25, 2023 | seekingalpha.comNabriva Therapeutics Provides Corporate UpdateJanuary 6, 2023 | finance.yahoo.comNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial DataNovember 28, 2022 | marketwatch.comNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic FibrosisNovember 28, 2022 | markets.businessinsider.comNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock UpNovember 28, 2022 | markets.businessinsider.comNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | bizjournals.comNabriva gains after announcing Phase 1 data for cystic fibrosis candidateNovember 28, 2022 | seekingalpha.comNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNovember 28, 2022 | finance.yahoo.comNabriva's stock is up after sharing antibiotic newsNovember 28, 2022 | finance.yahoo.comNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | finance.yahoo.comNabriva Therapeutics describes new 12-epi-mutilin compounds to treat bacterial infectionsNovember 10, 2022 | bioworld.comBMontgomery County biopharmaceutical firm reducing workforce by 40%November 10, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingRegional Bank Buybacks: 5 Institutions Making Big MovesBy Leo Miller | June 24, 2025View Regional Bank Buybacks: 5 Institutions Making Big MovesATHA, NBRV, MURA, and CNTB Company DescriptionsAthira Pharma NASDAQ:ATHA$0.30 -0.01 (-2.64%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.30 +0.01 (+3.05%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Connect Biopharma NASDAQ:CNTB$1.00 +0.03 (+3.04%) Closing price 06/27/2025 03:46 PM EasternExtended Trading$1.10 +0.10 (+10.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Mural Oncology NASDAQ:MURA$2.48 0.00 (0.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.52 +0.04 (+1.61%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
